Sarah Cannon Research Institute.

Nashville, Tennessee 37239

66 studies enrolling now · 465 studies all time

What they study most

ALK-positive Advanced NSCLC, AML, Abiraterone Acetate, Acute Graft-versus-host Disease, Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Lymphoid Leukemia, Acute Myelogenous Leukemia, Acute Myelogenous Leukemia (AML), Acute Myeloid Leukemia, Acute Myeloid Leukemia (AML), Adamantinomatous Craniopharyngioma

Studies at this site

• A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer — Recruiting now
• The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) — Recruiting now
• A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer — Recruiting now
• Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer — Recruiting now
• Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma — Recruiting now
• A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors — Recruiting now
• Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers — Recruiting now
• A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers — Recruiting now
• Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab — Recruiting now
• A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) — Recruiting now
• A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors — Recruiting now
• A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors — Recruiting now
• Study of Oral MRT-2359 With Apalutamide in Prostate Cancer — Recruiting now
• Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer — Recruiting now
• Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer — Recruiting now
• A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors — Recruiting now
• TLN-372 in Advanced KRAS Mutant Solid Tumors — Recruiting now
• A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors — Recruiting now
• A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma — Recruiting now
• FOG-001 in Locally Advanced or Metastatic Solid Tumors — Recruiting now
• Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer — Recruiting now
• A Study to Investigate Ubamatamab With and Without REGN7075 in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) — Recruiting now
• Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers — Recruiting now
• Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors — Recruiting now
• Phase IIIb Study of Ribociclib + ET in Early Breast Cancer — Recruiting now
• A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract — Recruiting now
• First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors — Recruiting now
• A Study of JNJ-87890387 for Advanced Solid Tumors — Recruiting now
• Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer — Recruiting now
• A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel — Recruiting now
• Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer — Recruiting now
• A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies — Recruiting now
• SNV1521 in Participants With Advanced Solid Tumors — Recruiting now
• Study of REM-422 in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma — Recruiting now
• A Study of LY4175408 in Participants With Advanced Cancer — Recruiting now
• Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer — Recruiting now
• MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors — Recruiting now
• CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer — Recruiting now
• A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel — Recruiting now
• Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation — Recruiting now
• A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma — Recruiting now
• Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors — Recruiting now
• Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS — Recruiting now
• A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors — Recruiting now
• Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors — Recruiting now
• A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma — Recruiting now
• Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies — Recruiting now
• A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma — Recruiting now
• Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors — Recruiting now
• SNV4818 in Participants With Advanced Solid Tumors — Recruiting now